Literature DB >> 29314711

MiR-492 regulates metastatic properties of hepatoblastoma via CD44.

Julia von Frowein1, Stefanie M Hauck2, Roland Kappler3, Philipp Pagel4,5, Katrin K Fleischmann1, Thomas Magg1, Stefano Cairo6,7, Adelbert Roscher8, Dietrich von Schweinitz3, Irene Schmid1.   

Abstract

BACKGROUND & AIMS: MicroRNAs are important genetic regulators of physiological and pathophysiological processes including cancer initiation and progression of hepatoblastoma, the most common liver tumour in childhood. We aimed to identify malignant and metastasis promoting effects of miR-492, a miRNA, previously reported to be overexpressed in metastatic hepatoblastoma. Furthermore, we intended to evaluate its diagnostic and prognostic potential.
METHODS: Stable and transient overexpression of miR-492 in two liver tumour cell lines HepT1 and HUH7 was used to analyse features of metastatic tumour progression such as proliferation, anchorage-independent growth, migration and invasion. Via a mass spectrometry based proteomic screen, we investigated miRNA-492-dependent effects on proteome level and explored the underlying biology. One of the predicted target genes, CD44, was experimentally validated via luciferase assays. Diagnostic and prognostic properties of miR-492 were studied in hepatoblastoma tumour samples.
RESULTS: We show that miR-492 significantly enhances cell proliferation, anchorage-independent growth, migration and invasion of hepatoblastoma cells. We also identified and validated CD44, a transmembrane adhesion receptor for hyaluronan, as direct and functional target of miR-492. This miRNA has a strong direct impact on two CD44 isoforms (standard and v10). High miR-492 expression correlates with high-risk or aggressive tumours and further bears potential for predicting reduced event-free survival.
CONCLUSIONS: We identified miR-492 and its target CD44 as regulators of a number of biological features important for malignancy and metastasis. Furthermore, we demonstrated the diagnostic and prognostic potential of miR-492, a promising novel therapeutic target and biomarker for hepatoblastoma.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CD44; hepatoblastoma; metastasis; miR-492

Mesh:

Substances:

Year:  2018        PMID: 29314711     DOI: 10.1111/liv.13687

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Diagnostic and Prognostic Value of miRNAs in Hepatoblastoma: A Systematic Review With Meta-Analysis.

Authors:  Bin Wu; Kaikai Zhen; Lixia Guo; Chao Sun
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  βKlotho, a direct target of miR-206, contributes to the growth of hepatoblastoma through augmenting PI3K/Akt/mTOR signaling.

Authors:  Tong Chen; Jianglong Chen; Xiuhao Zhao; Jing Zhou; Qingfeng Sheng; Linlin Zhu; Zhibao Lv
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

Review 3.  Non-Coding RNAs in Pediatric Solid Tumors.

Authors:  Christopher M Smith; Daniel Catchpoole; Gyorgy Hutvagner
Journal:  Front Genet       Date:  2019-09-20       Impact factor: 4.599

4.  Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma.

Authors:  Johannes Fänder; Heike Kielstein; Maximilian Büttner; Peter Koelblinger; Reinhard Dummer; Marcus Bauer; Diana Handke; Claudia Wickenhauser; Barbara Seliger; Simon Jasinski-Bergner
Journal:  Oncotarget       Date:  2019-11-05

5.  Analysis of Cells Proliferation and MicroRNAs Expression Profile in Human Chondrosarcoma SW1353 Cells Exposed to Iodine-125 Seeds Irradiation.

Authors:  Fusheng Li; Jia Xu; Yue Zhu; Liang Sun; Renyi Zhou
Journal:  Dose Response       Date:  2020-04-23       Impact factor: 2.658

6.  miR-492 Promotes Cancer Progression by Targeting GJB4 and Is a Novel Biomarker for Bladder Cancer.

Authors:  Kai Wang; Hang Lü; Hongchen Qu; Qingpeng Xie; Tao Sun; Ou Gan; Bin Hu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

Review 7.  CD44 as a tumor biomarker and therapeutic target.

Authors:  Hanxiao Xu; Mengke Niu; Xun Yuan; Kongming Wu; Aiguo Liu
Journal:  Exp Hematol Oncol       Date:  2020-12-10

8.  Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis.

Authors:  Yue Chang; Min Hao; Ru Jia; Yihui Zhao; Yixuan Cai; Yun Liu
Journal:  Cancer Cell Int       Date:  2021-01-07       Impact factor: 5.722

9.  Circulating miRNAs in Serum as Biomarkers for Early Diagnosis of Non-small Cell Lung Cancer.

Authors:  Xiaotong Duan; Simiao Qiao; Dianhe Li; Shangbiao Li; Zhihao Zheng; Qin Wang; Xiaoxia Zhu
Journal:  Front Genet       Date:  2021-07-09       Impact factor: 4.599

10.  Association between miR-492 rs2289030 G>C and susceptibility to Hirschsprung disease in southern Chinese children.

Authors:  Yi Zheng; Yanqing Liu; Mi Wang; Qiuming He; Xiaoli Xie; Lifeng Lu; Wei Zhong
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.